West Pharmaceutical Services WST
Healthcare · Medical - Instruments & Supplies · Synthos Deep Dive · 2026-07-03
The Overview
West Pharmaceutical makes the tiny rubber and glass parts that seal and deliver injectable medicines — the stoppers on vaccine vials, the plungers in pre-filled syringes, the seals on insulin and GLP-1 (weight-loss drug) cartridges. Almost every shot you've ever gotten touched a West-made component. It's a quiet, boring, extremely high-quality business: it makes a lot of profit on every dollar of sales and carries more cash than debt.
The catch: the stock has run up a lot — up about 64% in the past year — and is now expensive. You'd be paying roughly $42 for every $1 of next year's earnings, which is a rich price for a company only growing sales about 6% a year. Even Wall Street's own analysts have price targets below where the stock trades today. So our verdict is Watch — a great company, but wait for a cheaper entry.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit elevated). The company itself is rock-solid, but the price is high and the stock is "overbought" (it's climbed fast), so a stumble could sting.
- Growth Quality 7/10 (good). A very profitable, durable business — but growing modestly, not explosively.
- Exponential Potential 4/10 (modest). Steady grower, not a rocket. Don't expect it to double quickly.
The one big worry: you're paying a premium price for modest growth. If demand for injectable-drug components hiccups again — as it did in 2024–25 when customers had too much inventory — the expensive stock could fall meaningfully.
Putting a number on it: our fair-value estimate is $316 against a current price of $337.47 — a premium price for a business we still like.
Our summary metrics
Fortress net-cash balance sheet & low D/E — but 42× FY26E for ~6% revenue growth, RSI 83, trading ABOVE the Street's own targets.
Elite margins & returns on capital, but revenue CAGR only ~6% FY25→30E; EPS growth is off a depressed 2025 trough, not a new secular gear.
Picks-and-shovels beneficiary of GLP-1 & biologics, but ~6% top-line, decelerating past the recovery, and a $26B cap in a niche TAM cap the multibagger.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Picks-and-shovels beneficiary of GLP-1 & biologics, but ~6% top-line, decelerating past the recovery, and a $26B cap in a niche TAM cap the multibagger.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $339 (high $400 / low $295; 11 Buy · 3 Hold · 1 Sell) — note: consensus sits below the current price |
| Valuation | 49× trailing EPS · 42× FY26E · 38× FY27E · 29× FY30E · EV/S 8.0× · EV/EBITDA 30× |
| Technicals | Extended — $365.74 at the 52-wk high, RSI(14) 83 (overbought), +64% 12-mo (SPY +21%), but −22% max drawdown in the last year |
| Conviction | Low — 0 expert voices in the Synthos KB; call rests on fundamentals + quant |
| Position sizing | If owned, small — ≤2%; more likely a watch-and-wait for a better entry |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for WST — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $337.47, 3% below the 50-day average ($350), 16% above the 200-day average ($292) — a mixed trend. 8% below the 52-week high of $366, 46% above the 52-week low of $231.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $337.47 is currently at/below the lower band (potentially oversold) (band $342–$357).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 39.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 1.16, negative momentum.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = WST · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
West Pharmaceutical Services (NYSE: WST), founded in 1923 and headquartered in Exton, Pennsylvania, is the global leader in containment and delivery components for injectable drugs — elastomer stoppers and seals, syringe and cartridge parts, and self-injection/drug-delivery systems. If a medicine is injected, there is a high chance a West component seals the vial or delivers the dose. The business splits into two units:
- Proprietary Products — the high-value core: elastomer components (Westar, NovaPure), Crystal Zenith cyclic-olefin vials/syringes, and delivery devices (SmartDose). This is where the moat and the margin live.
- Contract-Manufactured Products (rebranded "West Vantage") — design and automated assembly of devices for surgical, diagnostic, ophthalmic and drug-delivery applications.
Fiscal year ends December 31.
Revenue mix (FY2025, from filings):
- By segment: Proprietary Products $2,492.1M (81%) · Contract-Manufactured / West Vantage $582.0M (19%). The high-margin proprietary segment carries the economics.
- By geography: United States $1,329.6M (43%) · Germany $380.3M · Ireland $333.3M · France $226.6M · other Europe $451.0M · other $353.3M. More internationally balanced than most US healthcare names — roughly 57% ex-US.
- By end market (Q1'26 mgmt): Biologics 42% · Pharma 25% · Generics 15% · Contract/West Vantage 18%. GLP-1-related elastomer revenue is ~10% of company sales and the fastest-growing category.
2. The expert thesis — (no KB coverage)
There is no expert coverage of WST in the Synthos knowledge base: total_claims = 0, zero net-bullish voices. No claim_ids exist to cite, and per house standard we will not manufacture conviction we do not have. This verdict is therefore fundamentals- and quant-driven: it rests on the reported financials, the analyst-estimate consensus (labeled as estimates), the valuation math, and management's own dated guidance (§9, half-weighted) — not on any distilled expert panel.
That absence is itself information: WST is a high-quality but under-followed "boring compounder" that the Synthos expert panel (which skews toward frontier/AI and high-conviction growth names) simply has not flagged. Read the scores and the bull/base/bear below as a quant-and-fundamentals judgment, not a chorus of experts.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Elevated | The balance sheet is a fortress — net cash (net debt −$375M, net-debt/EBITDA −0.24×), D/E 0.11, interest coverage enormous. But the stock is the risk: 42× FY26E for ~6% revenue growth, RSI 83 (overbought), at a 52-wk high, and trading above the Street's $339 consensus target. Beta 1.18. |
| Growth Quality | 7 · Good | Elite margins (36% gross, 26% EBITDA TTM) and returns (ROE 18%, ROIC 15%, ROCE 19%), durable moat, expanding high-value-product mix. Held back from higher only because revenue CAGR is ~6% FY25→30E — quality is high, but the rate is modest. |
| Exponential Potential | 4 · Modest | A real GLP-1/biologics tailwind, but ~6% top-line, growth decelerating past the 2025-recovery bounce, and a $26B cap in a niche component TAM. This compounds; it does not multibag. A $3B name with these returns would score higher. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | GLP-1 + Annex 1 high-value-product conversion + biologics keep compounding; FY27E EPS beats to ~$10.50 (vs $9.58 cons); the market keeps paying a premium ~38×. | ~$395 (+8%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS $9.58; a high-quality but ~6%-growth compounder earns a still-premium ~33× (down from today's 38×). | ~$316 (−14%) |
| Bear | GLP-1/customer-destocking wobble repeats (as in 2024–25); FY27E EPS misses to ~$9.00 and the multiple de-rates to ~25× as the "growth premium" unwinds. | ~$225 (−38%) |
Synthos fair value = the base case, ~$316 (−14%), with the full $225–$395 span as the honest range. Note the base case is below today's price: on our math the stock has already priced in the recovery. The Street's $339 consensus likewise sits below the current $365.74 — the market is trading richer than either us or the sell-side. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). WST is a high-quality compounder, decidedly not an exponential:
- Forward growth: revenue CAGR FY25→FY30E ~6.0% ($3.07B → $4.11B, est.); EPS CAGR ~12.8% ($6.80 → $12.44 est.) as margin/mix improves. The near-term EPS pop (FY25 $6.80 → FY27E $9.58, ~19%/yr) is largely a recovery off a depressed 2025 trough — 2025 revenue grew only ~6% and EPS was below the 2021 peak of $8.90 — not a step-change to a new secular growth rate.
- Acceleration (2nd derivative): genuinely positive right now off the trough — Q1'26 reported sales +21%, organic +15.3%, adj. EPS +47% YoY as GLP-1 and destocking normalized. But the estimate curve decelerates after the bounce: revenue est. growth ~8% (FY26E) → ~6% (FY27E) → ~7% (FY28E) → ~7.5% (FY29E) → ~1.4% (FY30E). The recovery is real; a durable acceleration is not in the numbers.
- Room to run: the injectable-component TAM is solid and GLP-1/biologics extend it, but it is a niche relative to a $26B cap. A 3× from here implies a ~$78B company in a component category — a stretch, not a base case.
- Reinvestment runway: heavy, productive capex (~$286M FY25, ~9% of revenue) into high-value-product capacity (Annex 1, GLP-1, biologics) — the reinvestment story is intact and is the main organic lever.
Exponential Potential: Modest (4/10). Own it, if at all, for durable low-teens earnings compounding and a wide moat — not for a fast multibagger. The honest framing keeps it out of any "exponential" sleeve.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $3,073.7M, +6.3% (FY24 $2,892.7M, −2.0% on FY23 $2,951.1M). Note the 2023–24 flat-to-down patch — the GLP-1/COVID-era destocking downturn — from which 2025–26 is the recovery.
- Quarterly trajectory (the recovery): Q1'25 $698.2M → Q2 $766.2M → Q3 $804.3M → Q4 $805.0M → Q1'26 $844.9M (+21.0% YoY). Reacceleration is clear and recent.
- Margins: gross 36.2% TTM, EBITDA 26.2%, operating 20.7%, net 16.9%. Elite for a components/manufacturing business; mix shift to high-value products is pushing them higher (Q1'26 gross margin 35.1%, +190 bps YoY).
- Earnings: net income $493.7M FY25 (roughly flat vs FY24 $492.7M, but below the 2021 peak $661.8M); diluted EPS $6.80. Q1'26 net income $138.8M, diluted EPS $1.92 (GAAP) / $2.13 adjusted.
- Cash flow: operating CF $754.8M FY25, capex −$285.9M (the HVP buildout), FCF $468.9M. FCF is real and growing, though the FCF yield is thin (~1.8%) at this valuation.
- Balance sheet: net cash — cash $791.3M vs total debt $416.7M, net debt −$374.6M, net-debt/EBITDA −0.24×, current ratio 2.7×. A genuine fortress; downside protection is on the balance sheet, not the multiple.
- Returns on capital: ROE 17.9%, ROIC 15.2%, ROCE 19.4% — consistently well above cost of capital, the signature of a durable moat.
6. Valuation — priced in or room?
This is the crux of the Watch. On every lens WST is expensive: 49× trailing EPS, 42× FY26E, 38× FY27E, 8.0× sales, 30× EV/EBITDA, 56× FCF. The bull's defense is the recovery-driven EPS ramp — the forward multiple compresses to 29× by FY30E if estimates hit. But that still leaves a ~6%-revenue-growth business at a near-30× exit multiple five years out. The PEG (~2.8× trailing, ~4.3× forward on FMP's calc) confirms you are paying up.
The starkest tell: the Street's own consensus price target ($339, median $320) is below the current $365.74 — the sell-side, which is usually generous, thinks the stock has run past fair value. Our base-case FV of ~$316 is close to the Street and ~14% below the price action. There is no way to call this cheap; it is a quality-compounder-well-above-fair-value — hence Watch, wait for a pullback.
7. Technicals (from the tech block)
- Trend: up, but extended. $365.74 is literally at the 52-week high (0.0% off), above the 50-DMA ($319.81) and 200-DMA ($275.98) with the 50 above the 200 (golden-cross posture). MACD +12.9 (positive).
- Location: +74% off the 52-week low ($210.08) but note a −22.4% max drawdown within the trailing year — this is not a low-volatility name; it round-tripped a big move.
- Momentum: RSI(14) 82.7 — clearly overbought (>70). This is a stretched-entry warning: the last leg has been sharp and one-directional.
- Relative strength: WST +64.4% 12-mo vs SPY +20.6% and QQQ +30.3%; +44.7% 3-mo vs SPY +13.7%. Powerful outperformance — which is exactly why the entry looks late.
- Read: technicals confirm a strong uptrend but flash "extended" — at the high with RSI 83, this is a poor spot to initiate. A pullback toward the rising 50-DMA (~$320) would offer a far better risk/reward and would roughly coincide with our base-case fair value.
8. Moat & competitive position
West's moat is specification lock-in: its elastomer components are written into customers' regulatory filings (the drug's approved manufacturing spec). Switching suppliers can force costly, time-consuming re-validation and re-filing with the FDA/EMA, so once West is "spec'd in," it tends to stay for the life of the drug. Layer on (1) decades of regulatory/quality know-how, (2) the Annex 1 sterile-manufacturing upgrade cycle driving a mix shift to high-value products, and (3) scale in a business where quality failures are catastrophic — and you get durable pricing power and 15–19% returns on capital. The main risks are customer destocking cycles (which hit hard in 2024–25) and gradual competition in commodity components from Aptar, Datwyler, and Stevanato.
Peer set (market cap, from FMP): Illumina $28.5B, Waters $24.7B, Quest Diagnostics $23.9B, Labcorp $23.5B, Incyte $23.3B, STERIS $21.3B, Hologic $17.0B, Zimmer Biomet $16.9B, Medpace $15.9B, Cooper Companies $14.5B. WST commands one of the richest multiples in this life-sciences-tools/med-supply group — justified by its returns and moat, but leaving little valuation cushion.
9. Management, capital allocation & guidance
- Leadership: President/CEO/Chair Eric M. Green; CFO Bob W. McMahon. ~10,600 employees.
- Capital allocation: disciplined and shareholder-friendly — FY25 $134M of buybacks (and an aggressive $297.6M in Q1'26 alone) plus a modest, growing dividend (~$61M, payout ~11%, yield ~0.24%), all funded from FCF while holding net cash. Heavy organic capex (~$286M) into high-value-product capacity is the primary growth lever. Appropriate for a business at ~15% ROIC.
- Insider activity: the sampled Form-4 window (through 2026-07-01) shows routine director stock/phantom-unit awards and an officer's option-exercise/tax-withholding cluster (Campbell, May 2026) — normal compensation mechanics, no alarming discretionary selling.
- Management's own guidance (half-weighted — their book): the SEC 8-K (Q1'26 earnings deck, filed 2026-04-23) is a genuine earnings release. Management's forward framing: ~200 bps of FY26 revenue-growth contribution from Annex 1 high-value-product conversion; GLP-1 called the "fastest-growing category, multi-year opportunity" (elastomer ~10% + West Vantage GLP-1 ~8% of Q1'26 sales); continued mix shift to high-margin HVP; the SmartDose transaction to AbbVie expected to close mid-2026; and the new Dublin West Vantage site now fully operational. Treat as management's self-interested outlook — directionally useful, corroborated by the Q1'26 beat, but not independent. (A hard FY26 EPS/revenue guidance range was not cleanly extractable from the deck text captured; we rely on the analyst-estimate consensus for the point figures, labeled as estimates.)
10. Catalysts & what to watch
- Next earnings: 2026-07-23 (Q2'26; Street EPS $2.08, revenue ~$838M). The key lines: organic growth durability, GLP-1 component trajectory, and HVP mix/gross-margin progression.
- GLP-1 volumes: the single biggest swing — West is a direct beneficiary of injectable GLP-1 growth; any slowdown or a shift toward oral formulations would pressure the thesis.
- Destocking: confirmation that the 2024–25 customer-inventory correction is fully behind — a relapse is the bear case.
- Annex 1 HVP conversion: the ~200 bps/yr high-value-product upgrade cycle — margin and mix engine.
- SmartDose/AbbVie transaction: mid-2026 close and its effect on the delivery-device mix.
Thesis tripwires (what would change the call to a clearer Buy or Avoid): a pullback toward the ~$320 50-DMA with intact fundamentals → upgrade toward Buy; two consecutive quarters of organic deceleration or a destocking relapse → move toward Avoid.
11. Key risks
- Valuation / de-rating (the dominant risk): 42× FY26E for ~6% revenue growth, at a 52-wk high, RSI 83, and above the Street's own targets — any disappointment re-rates the multiple hard. This is the reason for the Watch.
- Customer destocking / cyclicality: demonstrated in 2024–25 when revenue went flat-to-down; the business is not immune to the drug-manufacturing inventory cycle.
- GLP-1 concentration in the growth story: ~18% of sales are GLP-1-linked (elastomer + West Vantage); a class slowdown or oral shift bites the growth premium.
- Customer concentration: large pharma customers wield pricing leverage; spec lock-in mitigates but does not eliminate.
- FX: ~57% of revenue is ex-US; a stronger dollar is a translation headwind.
- No expert corroboration: this call has zero KB conviction behind it — it is fundamentals/quant only, a lower-confidence posture by design.
12. Verdict, position sizing & monitoring
Watch. West Pharmaceutical is a genuinely elite franchise — spec-locked moat, fortress net-cash balance sheet, 15–19% returns on capital, and a real GLP-1/biologics tailwind now visible in the Q1'26 reacceleration. If the business were the only question, it would score as a quality compounder. But the stock has already discounted the recovery: at $365.74 it trades at 42× forward earnings for a ~6% revenue grower, at the 52-week high with RSI 83, above both our ~$316 base-case fair value and the Street's $339 consensus target. The honest posture is patience, not chase.
- Sizing: if an investor insists on exposure, keep it small (≤2%) and scale in on weakness; more appropriately, watch and wait for a pullback toward the ~$320 50-DMA / our fair-value zone, which would flip the risk/reward.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-07-23). Logged as a tracked Synthos call as of 2026-07-03 at $365.74.
- Single biggest risk: paying a large premium for modest growth — a GLP-1 or destocking wobble against a 42× multiple.
Provenance & disclosures
- Traceability: 0 KB claims — WST has no expert coverage in the Synthos knowledge base; this verdict is explicitly fundamentals- and quant-driven, and no
claim_ids are cited because none exist. Fabricated conviction is structurally impossible (and none is claimed here). - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-03 · no expert claims. Forward figures are analyst consensus (FMP), labeled as estimates.
- Management caveat: the §9 guidance is management's own earnings-release framing (SEC 8-K, 2026-04-23), half-weighted by design — directionally useful, not independent.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").